{"entity":{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","aka":[],"tldr":"A phase 3 trial of Radotinib HCl in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., now recruiting.","summary":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs is a phase 3 interventional study registered as NCT03459534 by Il-Yang Pharm. Co., Ltd., with 173 participants planned, started 2018-06-25 and due to reach its primary completion in 2027-06-30. Interventions recorded: Radotinib HCl.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03459534","url":"https://clinicaltrials.gov/study/NCT03459534"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03459534","phase":"3","setting":"A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib","sponsor":"Il-Yang Pharm. Co., Ltd.","enrolled":173,"outcomes":[]},"route":"/trials/nct03459534/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}]}}